Samuel Dickson, PhD, Pentara Corporation, Millcreek, UT, discusses the effectiveness of Souvenaid, a medical drink under investigation for the dietary management of early Alzheimer’s disease. ‘Time savings’ data suggest that the multi-nutrient supplement provides continued improvement over three years, unlike monoclonal antibodies which may diminish in effectiveness over time. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.